Patients have to be especially vigilant for signs of infection throughout treatment.
Remicade first received approval for sale in the US in August 1998. Within the European Union, remicade received approval for treating patients with Crohn's disease in August 1999 and with rheumatoid arthritis in February 2000. In the UK it is currently authorised for use in adults only. In a significant number of cases, the onset of active TB occurred after three or less infusions of remicade. However, as clinical experience with remicade is still limited, the occurrence of TB or of other infections after a longer period of treatment cannot be ruled out.